

UNDERSTAND AD

Atopic Dermatitis: from Education to Empowerment

The results from the *Understand AD* survey of 505 American adults with self-reported moderate-to-severe atopic dermatitis provide a snapshot of the impact of the disease. Atopic dermatitis is a chronic form of eczema.¹ It is characterized by unpredictable flare-ups triggered in part by a malfunction in the immune system.^{2,3,4,5} *Understand AD* is brought to you by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

PATIENTS REPORT ON THE BURDEN OF LIVING WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS



25% of respondents report they have switched doctors 3 or more times in the hopes of treating their moderate-to-severe atopic dermatitis more effectively



60% of respondents also report receiving a diagnosis of another allergic condition, including seasonal and food allergies



In the past month, **more than a quarter** of people surveyed report that they have had 10 or more nights of interrupted sleep

82% OF RESPONDENTS REPORT MAKING LIFESTYLE MODIFICATIONS BECAUSE OF MODERATE-TO-SEVERE ATOPIC DERMATITIS



63% report that they have tried to cover up their skin with certain types of clothing such as long pants, or have tried to cover up affected areas with make-up



41% report that they have less desire to participate in social or recreational activities such as exercise, concerts or movies




26% report a negative impact on their ability to be productive at work and **16%** have made career/job choices that limit their face-to-face interactions with others because of the disease




More than 1/3 report they have eliminated things from their life that they once enjoyed to try to avoid flares

DESPITE CURRENTLY AVAILABLE TREATMENT OPTIONS, PEOPLE LIVING WITH ATOPIC DERMATITIS STILL STRUGGLE TO MANAGE THEIR DISEASE

68% of respondents report that they **often or sometimes** experience flares while on treatment



Respondents report that they have tried a range of treatments to manage their disease



This survey was conducted online in the U.S. by Harris Poll on behalf of Sanofi Genzyme and Regeneron Pharmaceuticals, Inc. between July 28 and August 17, 2016. The research was conducted among 505 U.S. adults aged 18+ who self-reported being diagnosed by a physician with moderate or severe atopic dermatitis, eczema, or atopic eczema. Figures for age, sex, race/ethnicity, education, region, household income, and household size were weighted where necessary to bring them into line with their actual proportions in the population.

SOURCES

- <http://www.mountsinai.org/patient-care/health-library/diseases-and-conditions/atopic-dermatitis#risk> Accessed: August 31, 2016.
- National Institutes of Health (NIH). Handout on Health: Atopic Dermatitis (A type of eczema) May 2013. Available online: http://www.niams.nih.gov/Health_Info/Atopic_Dermatitis/default.asp. Accessed: August 31, 2016.
- Gittler JK, et al. Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. *J Allergy Clin Immunol.* 2012; 130:6. 1345-1354.
- Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. *J Clin Invest.* 2004;113:651-657.
- Lebwohl MG, Del Rosso JQ, Abramovits W, et al. Pathways to managing atopic dermatitis: consensus from the experts. *J Clin Aesthet Dermatol.* 2013;6(7 Suppl):S2-S18

US-ILF-13130 | US.DUP.16.09.033

© 2016 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved.

SANOFI GENZYME  REGENERON